Meet us at EuroPCR 2026
The Eclevar team, including our former Notified Body expert, on what cardiovascular trials need to satisfy Notified Body review.
Book a meeting ↗Whether you need a full service CRO or a senior CER consultant, Eclevar MedTech eliminates the root causes of Notified Body non conformities before the first draft reaches the reviewer: MEDDEV 2.7/1 rev.4 methodology, Article 61(4) equivalence, Annex XIV traceability and PMCF linkage, built in from day one.
Backed by private investors and venture capital. Funding & investors
In the xShare and European CRO Federation (EUCROF) Open Call for Clinical Research, the top Platinum Award went to Milo Health, the technology platform behind Eclevar's evidence and forecasting work, presented at the EUCROF 2026 conference in Amsterdam.
Platinum Award · xShare Open Call for Clinical Research, organised by EUCROF and co-funded by the European Union. Amsterdam, 2 February 2026.
From a single remediation mandate to a fully outsourced clinical evaluation report, scope the engagement to the problem in front of you.
You already have a major NCR or a deficiency letter. A senior consultant, backed by a former Notified Body reviewer, rebuilds the failing element and drafts the response: equivalence, SLR methodology, traceability or PMCF linkage.
Outsource the CER end to end: state of the art, MEDDEV 2.7/1 rev.4 literature review, equivalence, authoring and Notified Body Q&A, signed by expert clinicians and delivered as one consistent package with the SSCP.
Connect evidence generation to evaluation: PMCF surveys, registries and clinical investigations designed to close the exact gaps your clinical evaluation identifies, so each update cycle gets stronger, not longer.
If you are searching for a CRO or consultancy to help with your clinical evaluation, start here. A CER is not a writing exercise: it is an evidence architecture, and most submissions collapse at the same five load bearing points.
More than two thirds of Class IIb and Class III CER submissions under EU MDR receive a major non conformity, from insufficient safety evidence to missing PMCF feedback loops.
Each Q&A round adds 3 to 4 months. For many sponsors, cumulative delays exceed nine months: lost market access for every month the device is not on the shelf.
Every CER Eclevar authors is built against the same assessment logic your Notified Body uses. Our senior team includes a former Notified Body reviewer who has assessed hundreds of packages and knows exactly which evidence gaps trigger a major NCR, so we close them before submission, not after.
The result across Eclevar managed CER submissions in 2024 and 2025: zero major non conformities.
Four structural answers to the four most common major NCRs. Each one is engineered into the document before authoring begins.
We build a complete matrix mapping every residual risk in the CER to a specific clinical evidence source. Notified Bodies cannot find a gap because there are no gaps.
We build the full three dimensional similarity matrix, technical, biological and clinical, before equivalence is claimed. No assertion is made without documentation.
Full MEDDEV 2.7/1 Section 9 compliance: predefined strategy, explicit inclusion and exclusion criteria, PRISMA flow, and study appraisal with NICE or GRADE. No cherry picking.
Each PMCF objective is derived directly from a specific evidence gap identified in the clinical evaluation. The PMCF plan and the CER are two sides of a single document.
From state of the art definition to SSCP consistency, each deliverable is co-authored from the same verified source documents.
Pre evaluation definition of the state of the art for the device category, establishing benchmarks before the search begins.
MEDDEV 2.7/1 Section 9 compliant review with PRISMA flow and GRADE or NICE appraisal.
Full Article 61(4) coverage: technical, biological and clinical similarity, documented before the claim is made.
Critical appraisal of device specific data: clinical investigations, PMCF results and registries.
Full MEDDEV 2.7/1 rev.4 authoring with the Annex XIV traceability matrix embedded in the document.
Co-authored deliverables to ensure full internal consistency across the CER, the SSCP and the PMCF plan.
Sponsors across cardiovascular, dental, renal, neuro and wound care rely on Eclevar for clinical evaluation, PMCF and Notified Body strategy.
Eclevar partnered with Nihon Kohden to resolve the deficiencies Notified Body reviewers raise on Japanese device files for the EEG-1200K: anticipating reviewer expectations, structuring the clinical strategy and linking PMCF evidence to the points reviewers challenge.
"Eclevar shared their expertise in a way that allowed us to create documentation perfectly adapted to our needs. The team responded promptly and flexibly."Product Manager, Nihon Kohden Corporation
A reimbursement clinical trial run as a multi centre study in the UK, supporting market access for Meril's TAVI platform with evidence designed for both regulators and payers.
Dedicated clinical evaluation and post market evidence generation for advanced dental and restorative technologies.
Eclevar manages all upcoming PMCF studies on chronic diabetic foot ulcer devices for RegenLab, present in 160 countries. "Eclevar, with its tailor made approach and advanced MILO Studio platform, represents a major strategic asset." Antoine Turzi, CEO, RegenLab.
Documents are written the way a reviewer needs to read them, then challenged internally against Notified Body assessment logic before they ever leave the building.
Leads CER and PMCF authoring across franchises, with deep methodology expertise in MEDDEV 2.7/1 rev.4 literature review, equivalence files and Class III evidence packages.
Cardiac surgeon and former senior reviewer at a Notified Body (TUV SUD). Reviews every CER against the assessment frameworks reviewers actually apply, and leads pre submission alignment.
Senior clinical lead for Class IIb and Class III orthopaedic and spine implants, from state of the art definition to clinical data appraisal and benefit risk conclusions.
Pilote la réalisation des investigations cliniques et études PMCF en Europe. Qualification des sites, monitoring, TMF, ISO 14155:2020. Master Ingénierie de la Santé (Université Grenoble Alpes). Parcours : recherche clinique, cardiovasculaire, usability medical devices.
Leads clinical data management and the Milo platform, so PMCF and registry data feed the clinical evaluation with verified, consistent values.
Your first point of contact: scopes the CER gap assessment, aligns stakeholders and keeps sponsors connected to the right expert at the right moment.
Practical references written by Eclevar's senior team for regulatory and clinical leaders preparing EU MDR submissions.
Our expert guide on where clinical evaluation under EU MDR is heading, what Notified Bodies are signalling, and how sponsors should structure evidence now to stay ahead.
Free download · sent to your inboxPrefer answers on your own file? Book a free 30 minute gap assessment: we review your current evidence against the Notified Body checklist and outline exactly what is required to reach approval in a single round.
Free · 30 minutes · no obligationWhere our consultants, including our former Notified Body expert, are presenting and what we are building. Come and find us, or book a call.
The Eclevar team, including our former Notified Body expert, on what cardiovascular trials need to satisfy Notified Body review.
Book a meeting ↗
Prof. Mark DaCosta, COO and former Notified Body expert, joins the CSI Frankfurt speaker panel on EU MDR and the introduction of new devices.
See the session ↗
Our award winning platform reads a protocol and returns three costed scenarios, swift, base and conservative, plus a recruitment forecast: the same rigour behind our CER evidence planning.
Discover Milo ↗A clinical evaluation report (CER) is the document required by EU MDR 2017/745 that demonstrates, with clinical evidence, that a medical device is safe and performs as intended. It follows MEDDEV 2.7/1 rev.4 methodology and is assessed by your Notified Body as part of CE marking.
The most common root causes are missing Annex XIV residual risk to evidence traceability, equivalence claimed under Article 61(4) without a documented similarity demonstration, literature reviews that fail MEDDEV 2.7/1 Section 9 methodology, PMCF plans not linked to specific CER gaps, and no defined state of the art benchmark.
We build the full three dimensional similarity matrix covering technical, biological and clinical characteristics before any equivalence claim is made, so the Notified Body receives documentation rather than assertion.
CERs are authored by our medical writing team led by Pierre-Marie Boutanquoi and reviewed against Notified Body assessment logic by senior clinicians including Prof. Mark DaCosta, a former senior reviewer at a Notified Body (TUV SUD), before submission.
A typical submission goes through 3 to 4 question and answer rounds, with each round adding months. Eclevar targets a single round: pre submission alignment, a complete evidence architecture at first submission, then minor clarification queries only.
It depends on scope. A consultant fits a targeted problem: one deficiency, one equivalence file, one methodology rebuild. A CRO fits when the CER depends on wider evidence work: literature review at scale, PMCF data, registries and Notified Body Q&A management. Eclevar covers both models: consultant level seniority, including a former Notified Body reviewer, with the medical writing team and data infrastructure of a CRO behind it.
Yes. Remediation mandates start with a gap assessment of the deficiency letter, then we rebuild the failing element, equivalence, SLR methodology, traceability or PMCF linkage, and draft the response in the structure reviewers expect.
Under EU MDR each PMCF objective should close a specific evidence gap identified in the clinical evaluation. Eclevar co-authors the CER and the PMCF plan as two sides of a single evidence strategy, with direct gap mapping.
Book a free clinical evaluation report gap assessment. We will review your current evidence and outline exactly what is required to achieve approval in a single round.
Book a free CER strategy call